<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Disease in organ transplant recipients has been characterized by a high incidence of chronic infection (in up to 60% of acutely infected patients) with progressive fibrosis and eventual cirrhosis [
 <xref ref-type="bibr" rid="CR63">63</xref>–
 <xref ref-type="bibr" rid="CR66">66</xref>]. Reactivation of infection has been described in liver and allogeneic HSCT recipients, in whom nearly half of infections became chronic [
 <xref ref-type="bibr" rid="CR67">67</xref>–
 <xref ref-type="bibr" rid="CR69">69</xref>]. Liver transplant recipients appear to be at increased risk for chronic infection resulting from reactivation of HEV after transplantation, as well as acute graft hepatitis from reactivation or primary infection [
 <xref ref-type="bibr" rid="CR70">70</xref>]. Extrahepatic manifestations of infection in transplant recipients have included glomerulonephritis and neurologic involvement [
 <xref ref-type="bibr" rid="CR69">69</xref>, 
 <xref ref-type="bibr" rid="CR71">71</xref>].
</p>
